SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-195035
Filing Date
2021-06-21
Accepted
2021-06-21 16:06:10
Documents
12
Period of Report
2021-06-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d179736d8k.htm   iXBRL 8-K 31789
  Complete submission text file 0001193125-21-195035.txt   154336

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aeri-20210617.xsd EX-101.SCH 2916
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20210617_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20210617_pre.xml EX-101.PRE 11424
5 EXTRACTED XBRL INSTANCE DOCUMENT d179736d8k_htm.xml XML 3410
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 211030528
SIC: 2836 Biological Products, (No Diagnostic Substances)